Zhang, J., Y. Lin, C. Li, X. Zhang, L. Cheng, L. Dai, Y. Wang, F. Wang, G. Shi, Y. Li, Q. Yang, X. Cui, Y. Liu, H. Wang, S. Zhang, Y. Yang, R. Xiang, J. Li, D. Yu, Y. Wei, and H. Deng. 2016. IL-35 decelerates the inflammatory process by regulating inflammatory cytokine secretion and M1/M2 macrophage ratio in psoriasis. J. Immunol. 197: 2131–2144.
Due to an error in figure preparation, the H&E staining of Fig. 8B for pIL-35 at 0 d after the 3-wk treatment period was inadvertently duplicated from the DEX group shown at 0 d. The corrected version of Fig. 8 is shown below, with a corrected panel for the pIL-35 group at 0 d. The figure legend was correct as published and is shown below for reference. The figure has been corrected in the online version of the article, which now differs from the print version as originally published.
IL-35 had long-term efficacy in K14-VEGF-A-Tg mice. (A) Immediately after the 3-wk treatment period (indicated as 0 d) and at 45 d (indicated as 45 d) and 90 d (indicated as 90 d) after the 3-wk treatment period, mice psoriatic symptoms were assessed via macroscopic observation. Cumulative scores (erythema + scaling + thickness) are depicted in the right panels. (B) H&E staining of ear skin at 0, 45, and 90 d (original magnification ×40) is shown in the left panels. Pathological score of ear sections using the Baker scoring system is shown in the right panels. n = 7. Columns represent mean; bars represent SD. *p < 0.05, **p < 0.01, ***p < 0.001. ns, no significance.
- Copyright © 2020 by The American Association of Immunologists, Inc.
In this issue
